SVB Securities analyst David Risinger reiterated a Buy rating on HilleVax, Inc (HLVX – Research Report) on April 25. The company’s shares closed yesterday at $14.14.
According to TipRanks, Risinger is a 4-star analyst with an average return of 5.9% and a 54.18% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Halozyme, Eli Lilly & Co, and Roivant Sciences.
HilleVax, Inc has an analyst consensus of Moderate Buy, with a price target consensus of $23.00.
See Insiders’ Hot Stocks on TipRanks >>
HLVX market cap is currently $555M and has a P/E ratio of -2.78.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel vaccines. The firm’s initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
Read More on HLVX:
